Improved drug safety through intensive pharmacovigilance in hospitalized pediatric patients

Alan O Vázquez-Alvarez1, Lorena Michele Brennan-Bourdon2, Ana Rosa Rincón-Sánchez3

  • 1Instituto de Terapéutica Experimental y Clínica (INTEC). Departamento de Fisiología. Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.

Insights

Intensive pharmacovigilance effectively detected adverse drug reactions in hospitalized children. This approach improved drug safety by identifying probable and certain reactions, particularly with antibiotics, and reducing preventable harm.

Area of Science:

  • Pediatric pharmacovigilance
  • Drug safety research
  • Clinical pharmacology

Background:

  • Adverse Drug Reactions (ADRs) pose a significant risk in pediatric hospital settings.
  • Effective pharmacovigilance strategies are crucial for identifying and mitigating these risks.
  • Previous research highlighted the need for enhanced monitoring in pediatric populations.

Purpose of the Study:

  • To detect and analyze Adverse Drug Reactions (ADRs) in hospitalized pediatric patients.
  • To evaluate the effectiveness of Intensive Pharmacovigilance (IPV) in improving pediatric drug safety.
  • To identify specific drug classes and risk factors associated with ADRs in children.

Main Methods:

  • A prospective 6-month cross-sectional study was conducted in a pediatric hospital in Mexico.
  • Inclusion criteria encompassed hospitalized children aged 1 day to 18 years on at least one medication.
  • ADR detection utilized medical visits, phone calls, and spontaneous reports, with causality assessed using established scales.

Main Results:

  • Out of 1083 admissions, 19 ADRs were recorded, with most classified as probable (68.4%).
  • Antibiotics (AB) and an antiepileptic drug were frequently implicated, with a significant association between AB and ADRs (p < 0.05).
  • Increased hospital stay was linked to ADRs and concomitant medications (p < 0.05); severe ADRs included hemolysis and toxic epidermal necrolysis.

Conclusions:

  • Intensive Pharmacovigilance (IPV) proved effective for ADR prevention, detection, and treatment in hospitalized pediatric patients.
  • The intensive monitoring approach significantly amplifies ADR detection rates.
  • This strategy directly contributes to the overall improvement of drug safety in pediatric care.
Abstract

Related Concept Videos

Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.8K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
284
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
337
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
257
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
324
Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
17